Knowledge Base

Understanding Bucket vs Progressive Royalty Tiers in Pharma Licensing Deals

Mastering royalty structures in biotech and pharma licensing deals is critical for achieving the desired financial outcomes. Two key models to understand are bucket royalty tiers and progressive royalty tiers. These structures, based on estimated drug sales revenues, can dramatically affect your licensing agreement's economic value. Let's explore their nuances and impact.

Valuation of an R&D stage pharmaceutical drug: what are the key value drivers?

The development of a pharmaceutical drug takes on average 10.5 years with average costs of development ranging from $314mio to $2.8billion . Every time during those development years, when money has to be spent on the development process questions come up relating to the current and future value of the project. This article will dive deeper into answering these questions.

Knowledge Base

Understanding Bucket vs Progressive Royalty Tiers in Pharma Licensing Deals

Valuation of an R&D stage pharmaceutical drug: what are the key value drivers?

Discoverhow RIVAL will support your funding efforts